The bicyclam AMD3 100 story
The bicyclam AMD3 100 story
复制标题
DOI：
10.1038/nrd1134
复制
发表时间：
2003-07-01
影响因子：
120.1
通讯作者：
De Clercq, E
中科院分区：
文献类型：
--
作者：
De Clercq, E
Bicyclam AMD3100（一种趋化因子受体拮抗剂）的发现和开发突出了此类化合物在HIV感染、炎性疾病、癌症和干细胞动员方面的治疗潜力。在这里，我描述了AMD 3100的开发过程，大约15年前开始分离杂质，以及AMD 3100及其同类物的临床应用基础。
The discovery and development of the bicyclam AMD3100 - a chemokine receptor antagonist - has highlighted the therapeutic potential of such compounds in HIV infection, inflammatory diseases, cancer and stem-cell mobilization. Here, I describe the development process of AMD3100, which began about 15 years ago with the isolation of an impurity, and the basis for the clinical application of AMD3100 and its congeners.